Tags

Type your tag names separated by a space and hit enter

Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19.
JAMA Netw Open. 2021 11 01; 4(11):e2132540.JN

Abstract

Importance

Continuous assessment of the effectiveness and safety of the US Food and Drug Administration-authorized SARS-CoV-2 vaccines is critical to amplify transparency, build public trust, and ultimately improve overall health outcomes.

Objective

To evaluate the effectiveness of the Johnson & Johnson Ad26.COV2.S vaccine for preventing SARS-CoV-2 infection.

Design, Setting, and Participants

This comparative effectiveness research study used large-scale longitudinal curation of electronic health records from the multistate Mayo Clinic Health System (Minnesota, Arizona, Florida, Wisconsin, and Iowa) to identify vaccinated and unvaccinated adults between February 27 and July 22, 2021. The unvaccinated cohort was matched on a propensity score derived from age, sex, zip code, race, ethnicity, and previous number of SARS-CoV-2 polymerase chain reaction tests. The final study cohort consisted of 8889 patients in the vaccinated group and 88 898 unvaccinated matched patients.

Exposure

Single dose of the Ad26.COV2.S vaccine.

Main Outcomes and Measures

The incidence rate ratio of SARS-CoV-2 infection in the vaccinated vs unvaccinated control cohorts, measured by SARS-CoV-2 polymerase chain reaction testing.

Results

The study was composed of 8889 vaccinated patients (4491 men [50.5%]; mean [SD] age, 52.4 [16.9] years) and 88 898 unvaccinated patients (44 748 men [50.3%]; mean [SD] age, 51.7 [16.7] years). The incidence rate ratio of SARS-CoV-2 infection in the vaccinated vs unvaccinated control cohorts was 0.26 (95% CI, 0.20-0.34) (60 of 8889 vaccinated patients vs 2236 of 88 898 unvaccinated individuals), which corresponds to an effectiveness of 73.6% (95% CI, 65.9%-79.9%) and a 3.73-fold reduction in SARS-CoV-2 infections.

Conclusions and Relevance

This study's findings are consistent with the clinical trial-reported efficacy of Ad26.COV2.S and the first retrospective analysis, suggesting that the vaccine is effective at reducing SARS-CoV-2 infection, even with the spread of variants such as Alpha or Delta that were not present in the original studies, and reaffirm the urgent need to continue mass vaccination efforts globally.

Authors+Show Affiliations

nference, Cambridge, Massachusetts.nference, Cambridge, Massachusetts.nference, Cambridge, Massachusetts.nference, Cambridge, Massachusetts.nference, Cambridge, Massachusetts.nference, Cambridge, Massachusetts.nference, Cambridge, Massachusetts.nference Labs, Murgesh Pallya, Bengaluru, Karnataka, India.Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.nference, Cambridge, Massachusetts.nference, Cambridge, Massachusetts. nference Labs, Murgesh Pallya, Bengaluru, Karnataka, India.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34726743

Citation

Corchado-Garcia, Juan, et al. "Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19." JAMA Network Open, vol. 4, no. 11, 2021, pp. e2132540.
Corchado-Garcia J, Zemmour D, Hughes T, et al. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19. JAMA Netw Open. 2021;4(11):e2132540.
Corchado-Garcia, J., Zemmour, D., Hughes, T., Bandi, H., Cristea-Platon, T., Lenehan, P., Pawlowski, C., Bade, S., O'Horo, J. C., Gores, G. J., Williams, A. W., Badley, A. D., Halamka, J., Virk, A., Swift, M. D., Wagner, T., & Soundararajan, V. (2021). Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19. JAMA Network Open, 4(11), e2132540. https://doi.org/10.1001/jamanetworkopen.2021.32540
Corchado-Garcia J, et al. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19. JAMA Netw Open. 2021 11 1;4(11):e2132540. PubMed PMID: 34726743.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19. AU - Corchado-Garcia,Juan, AU - Zemmour,David, AU - Hughes,Travis, AU - Bandi,Hari, AU - Cristea-Platon,Tudor, AU - Lenehan,Patrick, AU - Pawlowski,Colin, AU - Bade,Sairam, AU - O'Horo,John C, AU - Gores,Gregory J, AU - Williams,Amy W, AU - Badley,Andrew D, AU - Halamka,John, AU - Virk,Abinash, AU - Swift,Melanie D, AU - Wagner,Tyler, AU - Soundararajan,Venky, Y1 - 2021/11/01/ PY - 2021/11/2/entrez PY - 2021/11/3/pubmed PY - 2021/11/16/medline SP - e2132540 EP - e2132540 JF - JAMA network open JO - JAMA Netw Open VL - 4 IS - 11 N2 - Importance: Continuous assessment of the effectiveness and safety of the US Food and Drug Administration-authorized SARS-CoV-2 vaccines is critical to amplify transparency, build public trust, and ultimately improve overall health outcomes. Objective: To evaluate the effectiveness of the Johnson & Johnson Ad26.COV2.S vaccine for preventing SARS-CoV-2 infection. Design, Setting, and Participants: This comparative effectiveness research study used large-scale longitudinal curation of electronic health records from the multistate Mayo Clinic Health System (Minnesota, Arizona, Florida, Wisconsin, and Iowa) to identify vaccinated and unvaccinated adults between February 27 and July 22, 2021. The unvaccinated cohort was matched on a propensity score derived from age, sex, zip code, race, ethnicity, and previous number of SARS-CoV-2 polymerase chain reaction tests. The final study cohort consisted of 8889 patients in the vaccinated group and 88 898 unvaccinated matched patients. Exposure: Single dose of the Ad26.COV2.S vaccine. Main Outcomes and Measures: The incidence rate ratio of SARS-CoV-2 infection in the vaccinated vs unvaccinated control cohorts, measured by SARS-CoV-2 polymerase chain reaction testing. Results: The study was composed of 8889 vaccinated patients (4491 men [50.5%]; mean [SD] age, 52.4 [16.9] years) and 88 898 unvaccinated patients (44 748 men [50.3%]; mean [SD] age, 51.7 [16.7] years). The incidence rate ratio of SARS-CoV-2 infection in the vaccinated vs unvaccinated control cohorts was 0.26 (95% CI, 0.20-0.34) (60 of 8889 vaccinated patients vs 2236 of 88 898 unvaccinated individuals), which corresponds to an effectiveness of 73.6% (95% CI, 65.9%-79.9%) and a 3.73-fold reduction in SARS-CoV-2 infections. Conclusions and Relevance: This study's findings are consistent with the clinical trial-reported efficacy of Ad26.COV2.S and the first retrospective analysis, suggesting that the vaccine is effective at reducing SARS-CoV-2 infection, even with the spread of variants such as Alpha or Delta that were not present in the original studies, and reaffirm the urgent need to continue mass vaccination efforts globally. SN - 2574-3805 UR - https://www.unboundmedicine.com/medline/citation/34726743/Analysis_of_the_Effectiveness_of_the_Ad26_COV2_S_Adenoviral_Vector_Vaccine_for_Preventing_COVID_19_ DB - PRIME DP - Unbound Medicine ER -